New research published today in a report from the IMS Institute for Healthcare Informatics – Delivering on the Potential of Biosimilar Medicines: The Role of Functioning Competitive Markets, highlights the opportunity for biosimilars to create savings of approx USD 110 billion for health systems across Europe and the U.S over the next five years. The report highlights that the extent to which biosimilars will provide these forecasted savings will depend on the policy and implementation approaches adopted by country healthcare systems.

The report, funded by Novartis, will …

• Novartis Access is a first-of-its-kind portfolio of products aimed at increasing access to medicines against cardiovascular diseases, diabetes, respiratory illnesses and breast cancer in low- and low-middle-income countries

• First Novartis Access shipment delivered to Kenya where almost 30% of people die from NCDs every year

Holzkirchen, World Child Cancer Day (March 1, 2016): Sandoz is pleased to announce that the first Novartis Access shipment has just been delivered to Kenya. This shipment includes medicines against cardiovascular …

• Sandoz acquires rights to PF-06438179 (biosimilar infliximab) in the European Economic Area (EEA)*

• Sandoz plans to complete Phase III development program and file for registration in the EU

• Deal strengthens Novartis immunology portfolio which includes investigational biosimilars adalimumab, etanercept and rituximab

Holzkirchen, 12 February, 2016 – Sandoz, a Novartis company and a global leader in biosimilars, announced today that it has acquired from Pfizer the rights for the development and commercialization of PF- …

Holzkirchen, February 15, 2016 – Sandoz, together with leading global charity World Child Cancer (WCC), is pleased to announce a new health initiative in the Philippines, aimed at improving the standard of care for children suffering from cancer.

Cancer survival rates for children in the Philippines are less than 20%, compared to an average of 80% in developed countries. The goal of the new partnership, further details of which will be announced next month, is to help “even the odds” by supporting the development of specialist treatment centers in the island region …

• Sandoz’ late-stage biosimilar pipeline gains momentum with sustained investment – five of 10 planned regulatory filings achieved

• Sandoz believes that the totality of evidence in its submission, including three pivotal clinical studies, demonstrates that the proposed biosimilar is highly similar to the reference product.

• Sandoz is the European market leader in both the daily G-CSF class and for biosimilar filgrastim.

Holzkirchen, 11 February, 2016 – Sandoz, a Novartis company and the global leader in biosimilars, …